After seven months of resisting a takeover bid from Canada’s Valeant Pharmaceuticals International, Allergan Inc. agreed on Nov. 17 to be acquired by Irish generic drug maker Actavis plc in a cash and stock deal valued at $66 billion. It was the largest M&A deal announced to date in 2014.

Cleary Gottlieb Steen & Hamilton and Weil, Gotshal & Manges are advising Actavis, while Latham & Watkins and Wachtell, Lipton, Rosen & Katz are representing Irvine, Calif.-based Allergan.